Human Genome

We will be pursuing Biotechnology Sector for reviewing R&D and efficacy claims vis a vis Conventional Big Pharma if any. Human Genome today reported a mixed Phase II for its lupus drug Benlysta the NYSE Pharma index trades on DRG and Biotechnology on BTK Human Genome was unfortunately down 11% seemingly without a corresponding real loss in the physical world..